Seek Returns

INSM vs. ZTS: Insmed vs. Zoetis Stock Comparison

How do Insmed (INSM) and Zoetis (ZTS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Insmed (INSM) and Zoetis (ZTS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but INSM is classified in Biotechnology while ZTS is classified in Pharmaceuticals.

Company profile comparison for Insmed (INSM) and Zoetis (ZTS)
Profile ItemINSMZTS
NameInsmed IncorporatedZoetis Inc. Class A Common Stock
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyPharmaceuticals
GICS Sub-IndustryBiotechnologyPharmaceuticals
Market Capitalization25.10 billion USD32.26 billion USD
CurrencyUSDUSD
ExchangeNasdaqNYSE
Listing DateJune 1, 2000February 1, 2013
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

INSM
ZTS
GSPC
Loading price history…
Insmed (INSM) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Insmed (INSM) and Zoetis (ZTS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Insmed (INSM) and Zoetis (ZTS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Insmed (INSM) and Zoetis (ZTS)
MetricINSMZTS
Total Return (1Y)-39.17%-30.10%
Total Return (3Y, Annualized)70.17%-20.42%
Total Return (5Y, Annualized)28.96%-16.87%

Risk Profile

Drawdown History

INSM
ZTS
GSPC
Loading price history…
Insmed (INSM) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Insmed (INSM) and Zoetis (ZTS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Insmed (INSM) and Zoetis (ZTS)
MetricINSMZTS
Volatility (1Y, Annualized)63.09%38.23%
Beta (5Y)0.800.66
Max Drawdown (5Y)-56.54%-70.45%
Avg. Volume (3M)2.76M4.65M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
INSM and ZTS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Insmed (INSM) and Zoetis (ZTS)
MetricINSMZTS
Sharpe Ratio (1Y)-0.69-0.90
Sortino Ratio (1Y)-1.04-1.10

Profitability

ROE (TTM)

Insmed (INSM) reports a negative ROE of -72.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Zoetis (ZTS) reports 57.63%, ranking against industry peers normally.

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

-72.45%

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
INSM
-72.45%
Min
-167.77%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

57.63%

Max
109.18%
ZTS
57.63%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Insmed (INSM) vs. Zoetis (ZTS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Insmed (INSM) reports a negative net margin of -39.85%, usually indicating a net loss over the period. Meanwhile Zoetis (ZTS) reports 26.41%, ranking against industry peers normally.

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

-39.85%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
INSM
-39.85%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.41%

ZTS
26.41%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Insmed (INSM) vs. Zoetis (ZTS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Insmed (INSM) reports a negative operating margin of -15.60%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Zoetis (ZTS) reports 38.19%, ranking against industry peers normally.

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

-15.60%

Max
83.12%
Q3
14.77%
Median
0.00%
INSM
-15.60%
Q1
-78.82%
Min
-207.40%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.19%

Max
83.12%
ZTS
38.19%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Insmed (INSM) vs. Zoetis (ZTS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Insmed (INSM) and Zoetis (ZTS)
MetricINSMZTS
ROE (TTM)-72.45%57.63%
ROA (TTM)-17.25%14.87%
Net Margin (TTM)-39.85%26.41%
Operating Margin (TTM)-15.60%38.19%
Gross Margin (TTM)84.40%71.65%

Growth

Revenue Growth

Insmed (INSM) at 66.73% sits in the top revenue growth quartile, while Zoetis (ZTS) at 2.28% is closer to the peer norm — faster top-line expansion for INSM.

Loading chart…
Insmed (INSM) vs. Zoetis (ZTS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Zoetis (ZTS) reports EPS growth of 10.05%, ranked against its industry; Insmed (INSM) has no EPS growth figure this period.

Loading chart…
Insmed (INSM) vs. Zoetis (ZTS): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Insmed (INSM) and Zoetis (ZTS)
MetricINSMZTS
Revenue Growth (YoY)66.73%2.28%
Revenue Growth (3Y CAGR)35.20%5.42%
EPS Growth (YoY)--10.05%
EPS Growth (3Y CAGR)--10.27%

Financial Strength

Current Ratio (MRQ)

Insmed (INSM) at 2.86 keeps current ratio within its industry’s typical mid-range, while Zoetis (ZTS) at 2.35 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for ZTS.

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.86

Max
25.13
Q3
12.13
Median
5.52
INSM
2.86
Q1
2.47
Min
0.10

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.35

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
ZTS
2.35
Min
0.10
Loading chart…
Insmed (INSM) vs. Zoetis (ZTS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both balance sheets lean debt-heavy versus peers, but ZTS is more stretched: Insmed (INSM) at 1.01 sits in the higher-leverage quartile and Zoetis (ZTS) at 2.80 is above its industry benchmark range.

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.01

Max
1.42
INSM
1.01
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.80

ZTS
2.80
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Insmed (INSM) vs. Zoetis (ZTS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Insmed (INSM) and Zoetis (ZTS)
MetricINSMZTS
Current Ratio (MRQ)2.862.35
Debt / Equity (MRQ)1.012.80
Net Debt / EBITDA--1.92

Dividends

Dividend Yield (TTM)

Insmed (INSM) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Zoetis (ZTS) reports a yield of 2.55%, ranking against industry peers normally.

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

INSM
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.55%

ZTS
2.55%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Insmed (INSM) vs. Zoetis (ZTS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Insmed (INSM) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Zoetis (ZTS) reports a payout of 35.24%, ranking against industry peers normally.

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

INSM
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.24%

ZTS
35.24%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Insmed (INSM) vs. Zoetis (ZTS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Insmed (INSM) and Zoetis (ZTS)
MetricINSMZTS
Dividend Yield (TTM)0.00%2.55%
Dividend Payout Ratio (TTM)0.00%35.24%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Zoetis (ZTS) trades at 13.50 times trailing earnings, ranked against its peers, while Insmed (INSM) has no P/E ratio this period.

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
INSM
--

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.50

Max
85.34
Q3
43.46
Median
26.69
ZTS
13.50
Q1
13.30
Min
0.07
Loading chart…
Insmed (INSM) vs. Zoetis (ZTS): INSM does not report P/E ratio, so it has no value marker; ZTS is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

On P/S ratio, both Insmed (INSM) at 16.52 and Zoetis (ZTS) at 3.40 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.52

Max
58.18
Q3
25.77
INSM
16.52
Median
7.30
Q1
3.01
Min
0.01

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.40

Max
58.18
Q3
25.77
Median
7.30
ZTS
3.40
Q1
3.01
Min
0.01
Loading chart…
Insmed (INSM) vs. Zoetis (ZTS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both look rich against book: Zoetis (ZTS) at 9.80 sits in the upper P/B ratio quartile, and Insmed (INSM) at 34.55 prices even higher, above its industry range.

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

34.55

INSM
34.55
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.80

Max
13.53
ZTS
9.80
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Insmed (INSM) vs. Zoetis (ZTS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Insmed (INSM) and Zoetis (ZTS)
MetricINSMZTS
P/E Ratio (TTM)--13.50
P/S Ratio (TTM)16.523.40
P/B Ratio (MRQ)34.559.80
Free Cash Flow Yield (TTM)-1.82%6.36%